Hormonal secretion and quality of life in Nelson syndrome and Cushing disease after long acting repeatable octreotide: a short series and update

Clinical management of persistent adrenocorticotropin hormone (ACTH) excess in Nelson syndrome (NS) and Cushing disease (CD) remains a challenge. Somatostatin and its analogs as octreotide decrease ACTH secretion through somatostatin receptors of pituitary cells. To our knowledge, there are no repor...

Full description

Saved in:

Bibliographic Details
Published in:	American journal of therapeutics Vol. 21; no. 4; pp. e110 - e116
Main Authors:	Arregger, Alejandro L, Cardoso, Estela M L, Sandoval, Olga B, Monardes Tumilasci, Elida G, Sanchez, Rocío, Contreras, Liliana N
Format:	Journal Article
Language:	English
Published:	United States 01-07-2014
Subjects:	Adrenocorticotropic Hormone - secretion Antineoplastic Agents, Hormonal - administration & dosage Antineoplastic Agents, Hormonal - therapeutic use Delayed-Action Preparations Female Humans Hydrocortisone - secretion Middle Aged Nelson Syndrome - drug therapy Nelson Syndrome - physiopathology Octreotide - administration & dosage Octreotide - therapeutic use Pituitary ACTH Hypersecretion - drug therapy Pituitary ACTH Hypersecretion - physiopathology Quality of Life Treatment Outcome
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Clinical management of persistent adrenocorticotropin hormone (ACTH) excess in Nelson syndrome (NS) and Cushing disease (CD) remains a challenge. Somatostatin and its analogs as octreotide decrease ACTH secretion through somatostatin receptors of pituitary cells. To our knowledge, there are no reports on the effect of long-acting repeatable octreotide (oct-lar) on hormonal secretion and quality of life in patients with NS and CD who failed conventional therapy. Herein, we describe the effects of treatment with oct-lar (20 mg/month intramurally) in 1 woman with NS and 2 women with persistent CD. Oct-lar therapy reduced ACTH secretion and improved the quality of life in NS patient. By contrast, in CD patients, it failed to control ACTH and cortisol secretion, and the quality of life remained unchanged.
Bibliography:	ObjectType-Case Study-2 SourceType-Scholarly Journals-1 ObjectType-Feature-4 content type line 23 ObjectType-Report-1 ObjectType-Article-3
ISSN:	1075-2765 1536-3686
DOI:	10.1097/MJT.0b013e318255bc07